Revenue segments as reported by the company.

Water

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IDEXX Laboratories

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IDEXX Labs reports robust Q4 performance, eyes international growth

IDEXX Laboratories delivered strong Q4 results with revenue and profit growth, driven by gains in key segments and customer retention.
While facing challenges from inflationary costs and international headwinds, the company aims for continued growth and market differentiation.
Opportunities lie in expanding organic revenue, focusing on international markets, and enhancing customer engagement for future success.

IDEXX reports robust Q1 performance, eyes pet oncology growth

IDEXX Laboratories delivered a strong Q1 performance with revenue and profit growth across segments.
The company's focus on innovation, cloud adoption, and pet oncology diagnostics positions it well for future growth.
Challenges include U.S. clinical vet visit trends and potential market share competition in lab modalities.
Opportunities lie in pet oncology diagnostics, cloud adoption, and international market growth for IDEXX.

IDEXX Laboratories excels in Q2, eyes pet healthcare trends

IDEXX Laboratories demonstrated robust growth in revenues and profitability, driven by strong performance in key segments.
While facing challenges in international markets and margin pressures, the company is poised to capitalize on pet healthcare trends.
Strategic initiatives like product launches and pricing adjustments position IDEXX well for sustained growth and market leadership.

IDEXX Laboratories excels in Q3 earnings amidst capacity challenges

IDEXX Laboratories demonstrated strong financial performance in Q3, driven by revenue growth and operational efficiency.
While facing challenges in clinical visit trends and capacity management, the company's strategic focus on innovation and market expansion positions it well for future growth.
Opportunities lie in addressing capacity constraints, expanding the sales force, and enhancing customer engagement through diagnostics testing.
Overall, IDEXX's commitment to providing integrated solutions and quality services underscores its resilience and potential for sustained success.

IDEXX Labs posts robust Q4 results, eyes growth through innovation

IDEXX Laboratories delivered strong financial performance in Q4 2023 and aims for continued growth in 2024.
The company's focus on innovation, customer feedback, and operational efficiency positions it well for future success.
Challenges include managing expenses, revenue diversification, and maintaining customer value perception.
Opportunities lie in organic revenue growth, margin improvement, and the launch of new diagnostic tests and platforms.

IDEXX Laboratories reports strong Q1 earnings and growth opportunities

IDEXX Laboratories delivered strong financial performance in Q1 2024, driven by solid organic revenue growth and profit gains.
The company remains committed to innovation, customer-centric solutions, and increasing standard of care in Companion Animal Healthcare.
Challenges in clinical visit growth levels and macro impacts on consumer demand are being addressed through operational focus and technology investments.
Opportunities for growth and improvement in software integration and diagnostic utilization dynamics present avenues for future success.

IDEXX Laboratories reports solid Q2 growth amidst sector challenges

IDEXX Laboratories navigated Q2 2024 with solid revenue growth and a focus on innovation and cost management. Despite challenges from sector trends and macroeconomic headwinds, the company remains optimistic about long-term growth prospects. Ongoing launches and a strong balance sheet position IDEXX well for future opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Pool

These charts show how some pandemic winners will keep delivering for shareholders.

2 Stocks With COVID Gains Wall Street Shouldn't Erase

A stalwart stock, according to legendary investor Peter Lynch, is a large, stable company that still has attractive growth potential.

IDEXX: The Robust Stalwart

IDEXX (IDXX) witnesses continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

IDEXX's (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays

IDEXX Laboratories, Inc. (IDXX) CEO Jay Mazelsky on Q4 2021 Results - Earnings Call Transcript

IDEXX Laboratories has directly benefitted from the COVID-19 pandemic as diagnostic testing of animals has increased. Share prices and earnings per share have been increasing consistently over the last decade.

IDEXX Laboratories And Its Real Value

Growth in CAG Diagnostics revenues and CAG Diagnostics capital instrument revenues drove IDEXX (IDXX) Q4 revenues.

IDEXX (IDXX) Q4 Earnings Beat Estimates, Gross Margin Up

Idexx (IDXX) delivered earnings and revenue surprises of 13.17% and 2.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Idexx Laboratories (IDXX) Tops Q4 Earnings and Revenue Estimates

WESTBROOK, Maine, Feb. 2, 2022 /PRNewswire/ -- Achieves 11% fourth quarter revenue growth as reported and 10.5% organic, driven by 13% CAG Diagnostics recurring revenue growth (reported and organic) Strong growth supported by record instrument placements, resulting in 14% year-over-year expansion of IDEXX's global premium instrument installed base Delivers full year EPS of $8.60, an increase of 28% on a reported basis and 29% on a comparable basis, supported by operating margin expansion of 330 basis points as reported and 220 basis points on a comparable basis Provides initial outlook for 2022 revenue of $3,500 million - $3,565 million, reflecting reported growth of 9% - 11% and organic growth of 10% - 12% Estimates 2022 EPS of $9.27 - $9.59, an increase of 8% - 11% as reported and 12% - 16% on a comparable basis, including an estimated $0.15 per share or ~2% EPS growth impact from higher projected international tax rates IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced fourth quarter and full year results, as well as an update on U.S. companion animal diagnostic trends. Fourth Quarter and Full Year Results The Company reports revenues of $801 million for the fourth quarter of 2021, an increase of 11% compared to the prior year period on a reported basis and 10.5% on an organic basis.

IDEXX Laboratories Announces Fourth Quarter and Full Year 2021 Results

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Idexx Laboratories (IDXX) to Report a Decline in Earnings: What to Look Out for

Following the partnership between IDEXX (IDXX) and PetDx , the test is likely to be available later in January to all veterinary customers of IDXX in the United States and Canada.

IDEXX (IDXX) Collaborates With PetDx for Canine Cancer Test

SAN DIEGO, Jan. 13, 2022 /PRNewswire/ -- PetDx® – The Liquid Biopsy Company for Pets™, dedicated to unleashing the power of genomics to improve pet health, announced today a collaboration with IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, to significantly broaden access to canine cancer liquid biopsy testing.  OncoK9®, PetDx's pioneering liquid biopsy test for the detection of cancer in dogs, will be available later this month to all veterinary customers, in the United States and Canada, served by IDEXX Reference Laboratories.

PetDx and IDEXX Expand Access to OncoK9, the Cancer Liquid Biopsy Test for Dogs

WESTBROOK, Maine, Jan. 13, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced today a series of product and service enhancements that enable veterinary practices to be more efficient, while managing increasing patient volumes. The enhancements provide deeper, actionable insights and personalized support to facilitate faster, more confident clinical decisions.

IDEXX Innovative Diagnostic and Software Solutions Provide Workflow Efficiency and Faster, More Confident Clinical Decisions

WESTBROOK, Maine, Jan. 13, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced today the expansion of its reference laboratory menu of tests and services that will enable veterinarians to better meet the challenges of diagnosing and treating cancer. Building on its expertise in cancer pathology, IDEXX continues to expand what's possible to enhance the lives of pets by providing veterinarians with comprehensive cancer diagnostics and support services.

IDEXX Enables Improved Cancer Diagnosis and Personalized Care through Expanded Oncology Offering

WESTBROOK, Maine, Jan. 11, 2022 /PRNewswire/ --  IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2021 fourth quarter and full year financial results for Wednesday, February 2, 2022 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m.

IDEXX Laboratories to Release 2021 Fourth Quarter and Full Year Financial Results

Distributor purchasing dynamics have an impact on IDEXX's (IDXX) reported sales of CAG products.

IDEXX's (IDXX) Low LPD Sales, Rise in Expenses Dampen Growth

Idexx Laboratories (IDXX) closed at $661.32 in the latest trading session, marking a +0.86% move from the prior day.

Idexx Laboratories (IDXX) Gains As Market Dips: What You Should Know

IDEXX's (IDXX) global Reference Lab businesses continue to be robust driven by high same-store volume growth with strong gains across testing categories.

IDEXX's (IDXX) Organic Growth Robust, LPD Revenues Decline

Idexx Laboratories (IDXX) closed at $645.02 in the latest trading session, marking a +0.78% move from the prior day.

Idexx Laboratories (IDXX) Outpaces Stock Market Gains: What You Should Know

Idexx Laboratories (IDXX) closed the most recent trading day at $596.35, moving -1.49% from the previous trading session.

Idexx Laboratories (IDXX) Dips More Than Broader Markets: What You Should Know

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?

Idexx (IDXX) Down 4.2% Since Last Earnings Report: Can It Rebound?

IDEXX' (IDXX) global Reference Lab businesses are robust driven by high same-store volume growth with strong gains across testing categories.

IDEXX (IDXX) CAG Placement Grows Globally, LPD Disappoints

IDEXX Laboratories, Inc. (IDXX) CEO Jay Mazelsky on Q3 2021 Results - Earnings Call Transcript

IDEXX's (IDXX) Q3 top line rides on strong sales at the CAG and Water businesses.

IDEXX (IDXX) Q3 Earnings Beat Estimates, Gross Margin Falls

Henry Schein

Omnicell

STERIS

With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.

Medical Products Stock Earnings on Nov 2: IDXX, STE & More

Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

News for IDEXX Laboratories Stock (IDXX)